Medacta Corporate
IT WORKS! Proven accuracy and effectiveness of MyKnee, patient matched cutting blocks

IT WORKS! Proven accuracy and effectiveness of MyKnee, patient matched cutting blocks

In 2009 Medacta® International launched MyKnee®, patient matched cutting blocks for knee replacement. Since then, several articles have been published on MyKnee® proving the two main benefits of patient matched technology: accuracy and effectiveness. 

IT WORKS! Proven accuracy and effectiveness of MyKnee®, patient matched cutting blocks

Since 2008, all major orthopaedic companies have developed and actively promoted patient matched technology. The advantages of patient matched technology can be instantly identified just by its name!

Patient matched technology should take into account accurate positioning of the implant, thus potentially increasing its survival rate. The patient matched guides reduce the volume of instrumentation, helping the hospital to reduce the time and costs (up to 66% savings) associated with washing, assembling and sterilisation procedures. The overall OR efficiency is consequently increased, with a potential increase of the number of cases per surgery session.
 


 

This is all theory…
Which company can actually demonstrate these benefits with its patient matched system?
Analysing the literature available on patient matched technology, it is immediately apparent that there is a shortage of publications, the few publications that are available show controversial results[1-5].

In 2009 Medacta® International launched MyKnee®, patient matched cutting blocks for knee replacement. Since then, several articles have been published on MyKnee® proving the two main benefits of patient matched technology: accuracy and effectiveness[6-11].

MyKnee® proven benefits

Accurate MyKnee® limb alignment: 100% of the cases within 2° from 180°, analyses a series of postop CT’s [7].
MyKnee® is more accurate than conventional procedures and computer assisted surgery[6].
Reliable MyKnee® size planning: 98% size-matching[9].
With MyKnee®, the hospital’s turnover could be increased up to $230,000 per year [10].

What are the main reasons for MyKnee®’s success?
MyKnee® is the only patient matched technology on the market that offers the surgeon a unique set of benefits. MyKnee® provides patient matched cutting blocks, not just pin positioners, which can be created from a CT or MRI image. The outcome of 4000 MyKnee® cases treated to date, clearly demonstrates the supremacy of CT technology over MRI, due to the increased precision in the definition of the bone structure anatomy. In addition, special cases like TKR with the presence of plates or screws or UKR revision, impossible with an MRI, can easily be performed with CT based technology.

All of this is made possible in just 3 weeks (worldwide) including the assistance of a personal MyKnee® technician for each surgeon. Medacta® International develops and manufactures MyKnee® in-house, ensuring timeliness and precision – well known attributes of “Swiss Made”.

MyKnee® cases are managed entirely online without the need to download specialist software to analyse the 3D pre-operative planning and ensuring complete accessibility.

Medacta® always offers more…
Together with MyKnee® standard cutting blocks, Medacta® International offers you MyKnee® MIS cutting blocks.

The reduced size, rounded edges and anatomical shape allow the MyKnee® MIS cutting blocks to flawlessly adapt to minimally invasive approaches.
The soft tissues are respected and the added benefits are accuracy and efficiency.

Finally, MyKnee® lends its benefits to the UNI compartmental knee replacement via MyKnee® UNI*, designed to prepare the GMK® UNI* tibial resection and accurately plan the femoral size.
It has been demonstrated that there are several causes of early UKR failure which include inaccurate instrumentation[12]. Therefore the accurate and reproducible technique of MyKnee® UNI* is crucial to guarantee safe implant positioning and potential increased survival rate.

MyKnee® offers the surgeon a wide range of options which can be adapted to different surgical scenarios alongside personalised service, proven product accuracy and effectiveness.

 

References

[1] Webb J et al, 12th EFORT congress, Copenhagen, Jun 1-4, 2011.
[2] Parker D et al, AOA NZOA Meeting, Rotorua, New Zealand, Oct 9-14, 2011.
[3] Noble JW et al, J Arth 2012, 27(1):153-155.
[4] Misur P et al, AOA NZOA Meeting, Rotorua, New Zealand, Oct 9-14, 2011.
[5] Klatt BA et al, J Arth 2008, 23(1): 26-29.
[6] Leon V, 6th M.O.R.E International symposium, Stresa, Italy, May 13-14, 2011.
[7] Baldo F et al, J Orthopaed Traumatol 2011, 12 (1): S23-S88.
[8] Müller et al, 71st Annual Congress of the SSOT, Lausanne, Switzerland, Jun 22-24, 2011.
[9] Koch P et al, 86th Annual Congress of the SOFCOT, Paris, France, Nov 7-11, 2011.
[10] Goldberg TD, 6th M.O.R.E International symposium, Stresa, Italy, May 13-14, 2011.
[11] Koch P, Leading Opinions - Orth & Rheum 2011(2): 32-35.
[12] Kasodekar VB et al, Singapore Med J 2006; 47(9) : 796.
* GMK® UNI and MyKnee® UNI are not cleared by FDA for distribution in US.